MAPT and dementia: To begin to expand the utility of these iPSC lines for researchers in the dementia fields, we used CRISPR/Cas9‐mediated genome editing to introduce pathogenic MAPT mutations into the newly characterized iPSC lines (Figure 4A; Table 2).